We report the case of a patient with ALK-rearranged NSCLC who presented acquired resistance to crizotinib and then alectinib. 
crizotinib
We report the case of a patient with ALK-rearranged NSCLC who presented acquired resistance to crizotinib and then alectinib. 
alectinib
However, the patient then received ceritinib, a 2nd generation ALK inhibitor, and achieved another partial response. 
ceritinib